Exclusive | Netflix exec goes ballistic after being fired for stunning 'trust exercise' confession at retreat: suit

A high-level executive at Netflix has been terminated from their position following a specific incident during a company retreat. According to reports, the executive made a confession to co-workers during a designated trust exercise, admitting to the use of drugs. The individual has since filed a lawsuit against the company, claiming that the termination was a direct result of disclosing their use of ketamine. The legal action centers on the executive's assertion that the substance in question was medically prescribed, and that this disclosure during the corporate event led to their immediate loss of employment. Coverage of the incident is appearing across several major outlets including the New York Post, Benzinga, NDTV, Hindustan Times, and the Daily Star. The New York Post describes the executive's reaction to the firing as going ballistic in their exclusive report on the suit.

Benzinga and Hindustan Times specifically highlight the financial stakes of the termination, noting that the executive lost a job valued at $1.1 million. NDTV emphasizes the legal nature of the dispute, focusing on the executive's claim that the ketamine use was prescribed for medical reasons, which forms the core of the lawsuit against the streaming giant. This situation highlights a conflict between corporate conduct policies and the disclosure of medical treatments during internal company functions. The context provided by the reports indicates that the disclosure occurred during a trust exercise, a setting typically designed to foster openness and transparency among employees. The matter has escalated into a legal battle because the executive contends that the use of the substance was not illicit but medical, yet the company responded by removing the employee from their million-dollar role. This creates a tension between the expectations of a corporate retreat and the legal protections regarding medical prescriptions.

Future developments will depend on the progress of the lawsuit filed by the former executive. The legal proceedings will likely examine whether the disclosure of prescribed medical ketamine use constitutes a valid reason for termination under the company's policies. Observers will be watching to see if Netflix provides a formal rebuttal to the claims made in the suit or if the case moves toward a settlement. The specific details regarding the nature of the trust exercise and the internal reaction of the co-workers involved may also surface as the legal discovery process unfolds in the coming weeks.